Osmosis Investment Management UK Ltd purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 90,311 shares of the biopharmaceutical company's stock, valued at approximately $11,410,000.
Other institutional investors have also added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the 4th quarter worth about $25,000. Persistent Asset Partners Ltd acquired a new position in shares of Gilead Sciences during the second quarter worth about $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at approximately $26,000. Finally, Wealth Preservation Advisors LLC lifted its stake in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 81 shares in the last quarter. 83.67% of the stock is owned by institutional investors.
Insider Activity
In other Gilead Sciences news, CEO Daniel Patrick O'day sold 15,000 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company's stock, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 87,000 shares of company stock valued at $11,562,960. Company insiders own 0.30% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on GILD. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target for the company in a research note on Wednesday, May 20th. HSBC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Truist Financial reduced their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a research note on Tuesday, July 7th. Wall Street Zen raised Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $158.04.
Check Out Our Latest Stock Report on Gilead Sciences
Gilead Sciences Price Performance
Shares of GILD opened at $146.12 on Monday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company's fifty day simple moving average is $131.97 and its 200 day simple moving average is $136.55. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a market cap of $181.18 billion, a price-to-earnings ratio of -54.73 and a beta of 0.32.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. During the same quarter last year, the company posted $2.01 earnings per share. The company's revenue for the quarter was up 10.6% compared to the same quarter last year. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
